2023 NCCN Information for all sarcoma subtypes:
NCCN Patient Guidelines for Soft Tissue Sarcoma
NCCN Guidelines for Bone Sarcoma
Non-coding RNAs in metabolic reprogramming of bone and soft tissue sarcoma: Fundamental mechanism and clinical implication, Huan-Huan Chen , Peng-Hui Hao, Fang-Yuan Zhang, Tie-Ning Zhang, Science Direct, Elsevier, Biomedicine & Pharmacotherapy, Vol. 160, April 2023
Prognostic impact of circulating tumor cells in patients with soft-tissue sarcomas: a prospective study, Julie Blanchi, Audrey Laroche-Clary, François Le Loarer, Benjamin Bonhomme, Antoine Italiano, Cancer Communications, February 3, 2023, (DOI: 10.1002/cac2.12389)
High-Grade Sarcomas with Myogenic Differentiation Harboring Hotspot PDGFRB Mutations
Josephine K. Dermawan, Sarah Chiang, Martee L. Hensley, William D. Tap, Cristina R. Antonescu, Science Direct, Elsevier, Modern Pathology, Vol. 36, Issue 5, originally published January 23, 2023 (DOI:https://doi.org/10.1016/j.modpat.2023.100104).
2022
Current Status and Future Directions of Immunotherapies in Soft Tissue Sarcomas, William G. J. Kerrison, Alexander T. J. Lee, Khin Thway, Robin L. Jones, Paul H. Huang, Emmy D. G. Fleuren, Biomedicines, February 28, 2023 (doi: 10.3390/biomedicines10030573)